Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Norethindrone Acetate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR known ✓ | P06401 | 6/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 6/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 5/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 4/20 | 1.00 |
| ▸ | AR | P10275 | 4/20 | 1.00 |
| ▸ | NR3C1 | P04150 | 4/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 3/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 2/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 2/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 2/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 1.00 |
| ▸ | TBXA2R | P21731 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 5/20 | 0.70 |
| ▸ | ESR1 | P03372 | 3/20 | 0.70 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.70 |
| ▸ | MAOA | P21397 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Norethindrone Acetate SCHEMBL14360522 | 1.00 | CYP3A4 (1.00) | CYP3A4PGRABCB11CYP2C19AR | |
| Norethindrone Acetate SCHEMBL11321479 | 1.00 | CYP3A4 (1.00) | CYP3A4PGRABCB11CYP2C19AR | |
| Norethindrone Acetate SCHEMBL14074495 | 1.00 | CYP3A4 (1.00) | CYP3A4PGRABCB11CYP2C19AR | |
| Norethindrone Acetate SCHEMBL37530 | 1.00 | CYP3A4 (1.00) | CYP3A4PGRABCB11CYP2C19AR | |
| Norethindrone Acetate SCHEMBL1232662 | 1.00 | CYP3A4 (1.00) | CYP3A4PGRABCB11CYP2C19AR | |
| Norethindrone Acetate SCHEMBL16757740 | 0.96 | CYP3A4 (0.93) | CYP3A4PGRABCB11CYP2C19AR | |
| Norethindrone Acetate SCHEMBL8038659 | 0.94 | CYP3A4 (0.89) | CYP3A4PGRABCB11CYP2C19AR | |
| Norethindrone Acetate SCHEMBL691854 | 0.94 | CYP3A4 (0.89) | CYP3A4PGRABCB11CYP2C19AR | |
| SCHEMBL11291553 | 0.92 | CYP3A4 (0.85) | CYP3A4PGRABCB11CYP2C19AR | |
| SCHEMBL9473282 | 0.91 | CYP3A4 (0.84) | CYP3A4PGRABCB11CYP2C19AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220117977-A1 | FORMULATIONS AND METHODS FOR PROVIDING PROGESTIN-ONLY CONTRACEPTION | ALLERGAN SALES, LLC (US) | 2022-04-21 | — | — | US | disclosed |
| US-20200061082-A1 | FORMULATIONS AND METHODS FOR PROVIDING PROGESTIN-ONLY CONTRACEPTION WHILE MINIMIZING ADVERSE SIDE EFFECTS ASSOCIATED THEREWITH | ALLERGAN SALES, LLC (US) | 2020-02-27 | — | — | US | disclosed |
| US-20190111063-A1 | FORMULATIONS AND METHODS FOR PROVIDING PROGESTIN-ONLY CONTRACEPTION WHILE MINIMIZING ADVERSE SIDE EFFECTS ASSOCIATED THEREWITH | ALLERGAN SALES LLC (US) | 2019-04-18 | — | — | US | disclosed |
| WO-2007022061-A2 | FORMULATIONS AND METHODS FOR PROVIDING PROGESTIN-ONLY CONTRACEPTION WHILE MINIMIZING ADVERSE SIDE EFFECTS ASSOCIATED THEREWITH | WATSON LABORATORIES, INC. (US) | 2007-02-22 | — | — | WO | disclosed |
| US-20070037780-A1 | Formulations and methods for providing progestin-only contraception while minimizing adverse side effects associated therewith | ALLERGAN SALES, LLC | 2007-02-15 | — | — | US | disclosed |
| US-20070037780-A1 | Formulations and methods for providing progestin-only contraception while minimizing adverse side effects associated therewith | ALLERGAN SALES, LLC | 2007-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200061082-A1 | FORMULATIONS AND METHODS FOR PROVIDING PROGESTIN-ONLY CONTRACEPTION WHILE MINIMIZING ADVERSE SIDE EFFECTS ASSOCIATED THEREWITH | SHBG, PGRMC2, CYP19A1 | PGR 5/4885CYP3A4 148/4885ABCB11 768/4885 |
| US-20190111063-A1 | FORMULATIONS AND METHODS FOR PROVIDING PROGESTIN-ONLY CONTRACEPTION WHILE MINIMIZING ADVERSE SIDE EFFECTS ASSOCIATED THEREWITH | SHBG, CYP19A1, CYP17A1 | PGR 4/4885CYP3A4 77/4885ABCB11 999/4885 |
| US-20070037780-A1 | Formulations and methods for providing progestin-only contraception while minimizing adverse side effects associated therewith | SHBG, CYP19A1, CYP17A1 | PGR 4/4885CYP3A4 77/4885ABCB11 999/4885 |
| US-20220117977-A1 | FORMULATIONS AND METHODS FOR PROVIDING PROGESTIN-ONLY CONTRACEPTION | SHBG, PGRMC2, GNRHR | PGR 6/4885CYP3A4 535/4885ABCB11 1348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.